Abstract : The WHO last week validated China's Sinopharm COVID-19 vaccine for emergency use, a move set to further expand global vaccine accessibility.
worker transports Sinopharm COVID-19 vaccine at the Phnom Penh
International Airport in Phnom Penh, Cambodia, April 28, 2021. (Photo by
DELHI, May 13 (Xinhua) — China’s Sinopharm COVID-19 vaccine, the first
non-Western vaccine supported by the World Health Organization (WHO),
is likely to be used in the COVAX program, which provides vaccines to
low- and middle-income countries, reported the Indian Express newspaper
WHO last week validated the China-developed vaccine for emergency use, a
move set to further expand global vaccine accessibility.
to the WHO, Sinopharm has an efficacy of about 79 percent for
symptomatic and hospitalised disease for all age groups. However, it
notes that since few adults aged over 60 were enrolled, the efficacy in
the age group is not clear, said an article in the paper.
Sinopharm vaccine is an inactivated coronavirus vaccine, which takes
the disease-carrying virus (SARS-CoV-2) and kill it utilizing heat,
chemicals or radiation, it said, quoting the WHO as saying that these
vaccines take longer to make and might need two or three jabs to be
WHO has not recommended an upper age limit on the use of this vaccine
“because preliminary data and supportive immunogenicity data suggest the
vaccine is likely to have a protective effect in older persons. There
is no theoretical reason to believe that the vaccine has a different
safety profile in older and younger populations,” said the report.
WHO has recommended that the vaccine be administered to adults aged 18
and above in a two-dose schedule with a gap of three to four weeks, it
About Xinhua Silk Road
Xinhua Silk Road (en.imsilkroad.com) is the Belt and Road Initiative (BRI) portal.China’s silk road economic belt and the 21st century maritime silk road website,includes BRI Policy, BRI Trade, BRI Investment, Belt and Road weekly, Know Belt and Road, and the integrated information services for the Belt and Road Initiative (BRI).
Source: China’s Sinopharm COVID-19 vaccine likely conducive to global vaccine accessibility: Indian newspaper